Healthcare providers are a trusted resource for individuals who are interested in learning more about their genetic testing options. The VERDI Study aims to help clarify the genetic testing process for patients and to provide better access to genetic testing.

Study goals

Our tool, the Video Education with Result Dependent dIsclosure (VERDI) model, is increasingly being used as a pre-genetic testing (pretest) option in the hopes of better serving more diverse patient populations at risk for hereditary cancers. We hope you will encourage your patients to enroll in the VERDI Study to help us identify and evaluate strategies to improve the accessibility of this model.

VERDI Study participants will be randomized to either view the video or meet with a genetic counselor. If a participant then decides they want to proceed with genetic testing, they would give a blood and saliva sample.

Collaboration

If your patient and/or their family has not yet received any genetic testing or genetic counseling, they may be eligible for this study. Please contact us to ensure that you receive proper credit in study publications if you are willing to help us to enroll your patients in the study. Our research team is available to answer questions about patient enrollment.

Clinical resources

Our study team is happy to discuss appropriate follow-up testing and other resources for your patient’s management and care. Please contact us if you would like us to review patient cases or refer you to available resources.

Eligible patients

Your patient may be eligible to participate in the VERDI Study if:

  • They are over 18 years of age.
  • They have a current or prior diagnosis of any of the following cancers:
    • Breast
    • Ovarian
    • Pancreatic
    • Prostate
    • Colorectal
    • Renal (kidney)
    • Melanoma
    • Sarcoma
  • They have had no prior genetic testing or genetic counseling.

How to refer patients

Please share this website with your patients: VERDIstudy.org

Questions?

If you have any questions about the study, please reach out to the VERDI Study team at any of our sites:

Cancer Institute of New Jersey (CINJ)/Rutgers
195 Little Albany St, Rm 1135
New Brunswick, NJ, 08901
Contact person: Brianna Jeffreys
bam219@cinj.rutgers.edu

Dana-Farber Cancer Institute – Longwood Medical Area
450 Brookline Avenue
Boston, MA 02215
617-632-4795
Contact person: Alison Slack
VERDIstudy@dfci.harvard.edu

Dana-Farber Cancer Institute – Merrimack Valley
5 Branch St.
Methuen, MA 01844
978-620-2020
Contact person: Maurice Brule
MauriceN_Brule@ dfci.harvard.edu

Dana-Farber Brigham Cancer Center – Foxborough
22 Patriot Pl
Foxborough, MA 02035
857-491-7187
Contact person: Nicole Houghton
nicole_houghton@dfci.harvard.edu

Dana-Farber Brigham Cancer Center at Milford Regional Medical Center
20 Prospect St
Milford, MA 01757
774-448-3720
Contact person: Michelle Kosinski
michelle_kosinski@dfci.harvard.edu

Dana-Farber/New Hampshire Oncology-Hematology
40 Buttrick Rd
Londonderry, NH 03053
Contact person: Lindsey Ginter
lindseyk_ginter@dfci.harvard.edu

Dana-Farber Brigham Cancer Center at South Shore Health
101 Columbian St
South Weymouth, MA 02190
781-624-4795
Contact person: Norah Fleming
norah_fleming@dfci.harvard.edu